| Astrid Rosa Velez, MD | |
|
6804 Cecelia Drive, New Port Richey, FL 34653-4935 | |
| (855) 232-0644 | |
| (888) 546-0488 |
| Full Name | Astrid Rosa Velez |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 6804 Cecelia Drive, New Port Richey, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649584715 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 17962 (Puerto Rico) | Secondary |
| 207Q00000X | Family Medicine | ME126989 (Florida) | Primary |
| Entity Name | Mobile Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003002759 PECOS PAC ID: 4688685654 Enrollment ID: O20060505000660 |
News Archive
Export Development Canada today announced a previously disbursed USD 67.5 M in financing for Montreal's Valeant Pharmaceuticals International, Inc., Canada's largest multinational pharmaceutical company.
A new study published in Scientific Reports reveals that the language people use on Facebook subtly changes before they make a visit to the emergency department.
Cells possess a variety of ways of dealing with mutations that can cause them to grow uncontrollably and eventually form a tumor. The tumor suppressor gene p53 plays a critical role in these cancer prevention processes, largely by triggering a form a cell death known as apoptosis.
Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.
› Verified 7 days ago
| Entity Name | Avs Medical Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891418141 PECOS PAC ID: 8224409537 Enrollment ID: O20230125000325 |
News Archive
Export Development Canada today announced a previously disbursed USD 67.5 M in financing for Montreal's Valeant Pharmaceuticals International, Inc., Canada's largest multinational pharmaceutical company.
A new study published in Scientific Reports reveals that the language people use on Facebook subtly changes before they make a visit to the emergency department.
Cells possess a variety of ways of dealing with mutations that can cause them to grow uncontrollably and eventually form a tumor. The tumor suppressor gene p53 plays a critical role in these cancer prevention processes, largely by triggering a form a cell death known as apoptosis.
Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Astrid Rosa Velez, MD 6804 Cecelia Drive, New Port Richey, FL 34653-4935 Ph: (855) 232-0644 | Astrid Rosa Velez, MD 6804 Cecelia Drive, New Port Richey, FL 34653-4935 Ph: (855) 232-0644 |
News Archive
Export Development Canada today announced a previously disbursed USD 67.5 M in financing for Montreal's Valeant Pharmaceuticals International, Inc., Canada's largest multinational pharmaceutical company.
A new study published in Scientific Reports reveals that the language people use on Facebook subtly changes before they make a visit to the emergency department.
Cells possess a variety of ways of dealing with mutations that can cause them to grow uncontrollably and eventually form a tumor. The tumor suppressor gene p53 plays a critical role in these cancer prevention processes, largely by triggering a form a cell death known as apoptosis.
Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.
› Verified 7 days ago
Dr. David Herndon, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5500 Little Rd, New Port Richey, FL 34655 Phone: 727-372-1005 Fax: 352-807-7081 | |
Dr. Richard Joseph Campanile, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 6804 Cecelia Dr, New Port Richey, FL 34653 Phone: 727-232-0644 Fax: 888-546-0488 | |
Juan A. Amador Tavarez, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8501 Little Rd, New Port Richey, FL 34654 Phone: 727-869-7755 Fax: 727-869-7372 | |
Dr. Maria Theresa L. Belicena, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6600 Madison St Fl 2, New Port Richey, FL 34652 Phone: 727-815-7207 Fax: 727-266-4951 | |
Kaloutie Singh, ARNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 9912 Little Rd, New Port Richey, FL 34654 Phone: 727-869-4125 | |
Dr. Ludonir Sebastiany, MD, MS Family Medicine Medicare: Medicare Enrolled Practice Location: 6804 Cecelia Drive, New Port Richey, FL 34653 Phone: 855-232-0644 Fax: 888-546-0488 | |
Arthur M Schlyer Jr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5411 Grand Blvd, Suite 107, New Port Richey, FL 34652 Phone: 727-847-1825 Fax: 727-849-4855 |